文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617放射配体治疗mCRPC的疗效与生存Meta分析

Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2018-01-01

该Meta分析纳入10项研究共455例转移性去势抵抗性前列腺癌患者,评估177Lu-PSMA-617首周期治疗后PSA应答及生存效应。汇总任何PSA下降比例为68.00%,>50%PSA下降比例为34.45%;任何PSA下降者总生存HR为0.29(P<0.00001),>50%PSA下降者HR为0.82(P=0.39)无统计学意义。作者认为首周期后约三分之二患者可出现任何PSA下降、约三分之一出现>50%下降,任何PSA下降与生存延长相关。

要点

  • 首周期177Lu-PSMA-617后任何PSA下降汇总比例68.00%(95%CI 63.55%-72.22%)。
  • >50%PSA下降汇总比例34.45%(95%CI 30.14%-38.97%)。
  • 任何PSA下降者总生存HR 0.29(95%CI 0.21-0.40,P<0.00001)。

核心结论

  • 作者认为mCRPC患者首周期177Lu-PSMA-617放射配体治疗后约三分之二可出现任何PSA下降、约三分之一可出现>50%PSA下降。
  • 任何PSA下降显示首周期177Lu-PSMA-617放射配体治疗后的生存延长。

研究设计与样本

  • Meta分析,最终纳入10项合格研究、共455例患者。
  • 主要结局为首周期177Lu-PSMA-617放射配体治疗后的治疗应答,参数为任何PSA下降与>50%PSA下降的汇总比例。
  • 次要结局为177Lu-PSMA-617放射配体治疗后的生存效应,参数为按首周期后任何PSA下降与>50%PSA下降分组的汇总总生存风险比。

主要发现

  • 任何PSA下降的汇总比例为68.00%(95%CI 63.55%-72.22%)。
  • >50%PSA下降的汇总比例为34.45%(95%CI 30.14%-38.97%)。
  • 任何PSA下降的总生存汇总HR为0.29(95%CI 0.21-0.40),P<0.00001。
  • >50%PSA下降的总生存汇总HR为0.82(95%CI 0.54-1.25),P=0.39,无统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a meta-analysis on the therapeutic effects of prostate-specific membrane antigen (PSMA)-617 labeled with lutetium-177 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The primary outcome was the therapeutic responses after the first cycle of Lu-PSMA-617 radioligand therapy. The parameters studied were the pooled proportions of any prostate-specific antigen (PSA) decline and a greater than 50% PSA decline. The secondary outcome was the survival effects after Lu-PSMA-617 radioligand therapy. Studied parameters were pooled hazard ratios of the overall survival according to any PSA decline and a greater than 50% PSA decline after the first cycle of Lu-PSMA-617 radioligand therapy. RESULTS: In total, 10 eligible studies with 455 patients were finally included in this meta-analysis. The pooled proportions of any PSA decline was 68.00% (95% confidence interval [CI], 63.55%-72.22%], and those with a greater than 50% PSA decline was 34.45% (95% CI, 30.14%-38.97%). The pooled hazard ratios for the overall survival of any PSA decline was 0.29 (95% CI, 0.21-0.40) with significance (P < 0.00001); however, a greater than 50% PSA decline was 0.82 (95% CI, 0.54-1.25) with no significance (P = 0.39). CONCLUSIONS: We suggest that approximately two-thirds of any PSA decline and one-third of a greater than 50% PSA decline can be expected after the first cycle of Lu-PSMA-617 radioligand therapy in patients with mCRPC. Moreover, any PSA decline showed survival prolongation after the first cycle of the Lu-PSMA-617 radioligand therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim YJ, Kim YI. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. Clin Nucl Med. 2018. PMID: 30059428. doi:10.1097/RLU.0000000000002210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。